Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma

被引：1
|
作者：
Lapuente, Maria [1 ]
Conway, Dawn [2 ]
Wood, Laura S. [3 ]
Kehoe, Kiran [4 ]
Bullock, Andrea Carroll [5 ]
Devgan, Geeta [6 ]
Burns, Kathleen D. [7 ]
机构：
[1] Bartholomews Hosp, London, England
[2] Univ Chicago Med Illinois, Genitourinary Oncol, Chicago, IL USA
[3] Cleveland Clin Ohio, Taussig Canc Ctr, Cleveland, OH USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] North Amer Med Commun EMD Serono, Rockland, MA, Brazil
[6] Pfizer, US Med Affairs, New York, NY USA
[7] City Hope Natl Med Ctr, Natl Canc Ctr, Duarte, CA USA
来源：
CLINICAL JOURNAL OF ONCOLOGY NURSING | 2023年 / 27卷 / 01期
关键词：
avelumab first-line maintenance; bladder cancer; immune-related adverse events; CHEMOTHERAPY; CANCER; CISPLATIN;
D O I：
10.1188/23.CJON.71-80
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND:The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.OBJECTIVES: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.METHODS: This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.FINDINGS: Oncology nurses can provide compre-hensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct adminis-tration, and promptly recognizing and managing immune-related adverse events.
引用
收藏
页码：71 / 80
页数：10
相关论文
共 50 条
  • [41] Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
    Gerullis, H.
    Eimer, C.
    Georgas, E.
    Barski, D.
    Otto, T.
    ONKOLOGIE, 2013, 36 : 115 - 115
  • [42] Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
    Gerullis, Holger
    Eimer, Christoph
    Ecke, Thorsten H.
    Georgas, Evangelos
    Arndt, Christian
    Otto, Thomas
    ANTI-CANCER DRUGS, 2013, 24 (04) : 422 - 425
  • [43] ONCOLOGISTS' PERSPECTIVES ON EVOLUTION OF FIRST-LINE IMMUNE CHECKPOINT INHIBITOR MAINTENANCE THERAPY IN MANAGEMENT OF ADVANCED UROTHELIAL CARCINOMA IN THE US
    Grivas, Petros
    Veeranki, Phani
    Chiu, Kevin
    Pawar, Vivek
    Chang, Jane
    Bharmal, Murtuza
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A660 - A660
  • [44] AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY FIRST-LINE CHEMOTHERAPY REGIMEN AND ANALYSIS OF OVERALL SURVIVAL FROM START OF FIRST-LINE CHEMOTHERAPY
    Sridhar, Srikala S.
    Powles, Thomas
    Gupta, Shilpa
    Climent Duran, Miguel A.
    Aragon-Ching, Jeanny B.
    Sternberg, Cora N.
    Cislo, Paul
    Costa, Nuno
    Salvo, Porto
    di Pietro, Alessandra
    Bellmunt, Joaquim
    Grivas, Petros
    JOURNAL OF UROLOGY, 2024, 211 (05): : E806 - E807
  • [45] Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
    Powles, Thomas
    Park, Se Hoon
    Caserta, Claudia
    Valderrama, Begona P.
    Gurney, Howard
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S. S.
    Sternberg, Cora N. N.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B. B.
    Wang, Jing
    Huang, Bo
    Laliberte, Robert J. J.
    di Pietro, Alessandra
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3486 - +
  • [46] AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL
    Grivas, Petros
    Bellmunt, Joaquim
    Park, Se Hoon
    Voog, Eric
    Mans, Le
    Caserta, Claudia
    Valderrama, Begona P.
    Gurney, Howard
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Sternberg, Cora N.
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Blake-Haskins, John A.
    Laliberte, Robert J.
    Wang, Jing
    Costa, Nuno
    Powles, Thomas
    JOURNAL OF UROLOGY, 2022, 207 (05): : E183 - E183
  • [47] Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study
    Grivas, Petros
    Barata, Pedro
    Moon, Helen
    Gupta, Shilpa
    Hutson, Thomas
    Sternberg, Cora N.
    Brown, Jason R.
    Dave, Vaidehi
    Downey, Chad
    Shillington, Alicia C.
    Katzenstein, Howard M.
    Kirker, Melissa
    Hanson, Sarah
    Liu, Frank X.
    Morris, Valerie
    Bhanegaonkar, Abhijeet
    Sonpavde, Guru P.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [48] How I Do It: Maintenance avelumab for advanced urothelial carcinoma
    Lalani, Aly-Khan A.
    CANADIAN JOURNAL OF UROLOGY, 2023, 30 (04) : 11633 - 11638
  • [49] Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan
    Shindo, Tetsuya
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (08) : 867 - 868
  • [50] Real-world data from early access and patient access programs of avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma in Australia
    Moujaber, Tania
    Tran Ben
    Liow, Elizabeth
    Clay, Timothy
    Bennett, Geer
    Kearney, Mairead
    Gibberd, Alison
    Gurney, Howard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 94 - 95
12345